Skin barrier dysfunction and filaggrin
- 주제(키워드) Skin barrier , Filaggrin , Atopic dermatitis , Skin disorders
- 주제(기타) Chemistry, Medicinal
- 주제(기타) Pharmacology & Pharmacy
- 설명문(일반) [Kim, Yeonjoon] Qmine Co Ltd, 122B,150 Bukahyun Ro, Seoul 03760, South Korea; [Lim, Kyung-Min] Ewha Womans Univ, Coll Pharm, Seoul 03760, South Korea
- 등재 SCIE, SCOPUS, KCI등재
- 발행기관 PHARMACEUTICAL SOC KOREA
- 발행년도 2021
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000182523
- 본문언어 영어
- Published As http://dx.doi.org/10.1007/s12272-021-01305-x
- PubMed https://pubmed.ncbi.nlm.nih.gov/33462753
초록/요약
Skin barrier dysfunction caused by endogenous or exogenous factors can lead to various disorders such as xerosis cutis, ichthyoses, and atopic dermatitis. Filaggrin is a pivotal structural protein of the stratum corneum (SC) and provides natural moisturizing factors that play a role in skin barrier functions. Filaggrin aggregates keratin filaments, resulting in the formation of a keratin network, which binds cornified envelopes and collapse keratinocytes to flattened corneocytes. This complex network contributes to the physical strength of the skin. Filaggrin is degraded by caspase-14, calpain 1, and bleomycin hydrolases into amino acids and amino acid metabolites such as trans-urocanic acid and pyrrolidone carboxylic acid, which are pivotal natural moisturizing factors in the SC. Accordingly, filaggrin is important for the pathophysiology of skin barrier disorders, and its deficiency or dysfunction leads to a variety of skin disorders. Here, the roles and biology of filaggrin, related skin diseases, and a therapeutic strategy targeting filaggrin are reviewed. In addition, several drug candidates of different mode of actions targeting filaggrin, along with their clinical efficacy, are discussed.
more